Approximately 1 in 20 adults with outpatient respiratory syncytial virus (RSV) infections were readmitted to the hospital ...

Hypertension, atrial fibrillation, and smoking were all strongly linked to a higher risk for severe stroke than non-severe ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...